Sonobactericide: An Emerging Treatment Strategy for Bacterial Infections by Lattwein, K.R. (Kirby) et al.
ARTICLE IN PRESS
Ultrasound in Med. & Biol., Vol. 00, No. 00, pp. 123, 2019
Copyright © 2019 The Author(s). Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology.
This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Printed in the USA. All rights reserved.
0301-5629/$ - see front matter
https://doi.org/10.1016/j.ultrasmedbio.2019.09.011 Review ArticleSONOBACTERICIDE: AN EMERGING TREATMENT STRATEGY FOR BACTERIAL
INFECTIONS
T AGGEDPKIRBY R. LATTWEIN,* HIMANSHU SHEKHAR,y JOOP J.P. KOUIJZER,* WILLEM J.B. VAN WAMEL,z
CHRISTY K. HOLLAND,y and KLAZINA KOOIMAN*T AGGEDEND
*Department of Biomedical Engineering, Thoraxcenter, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The
Netherlands; yDivision of Cardiovascular Health and Disease, Department of Internal Medicine, University of Cincinnati, Cincinnati,
Ohio, USA; and zDepartment of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam,
Rotterdam, The Netherlands
(Received 17 April 2019; revised 3 September 2019; in final from 16 September 2019)A
Biome
Medica
NetherAbstract—Ultrasound has been developed as both a diagnostic tool and a potent promoter of beneficial bio-
effects for the treatment of chronic bacterial infections. Bacterial infections, especially those involving biofilm on
implants, indwelling catheters and heart valves, affect millions of people each year, and many deaths occur as a
consequence. Exposure of microbubbles or droplets to ultrasound can directly affect bacteria and enhance the
efficacy of antibiotics or other therapeutics, which we have termed sonobactericide. This review summarizes
investigations that have provided evidence for ultrasound-activated microbubble or droplet treatment of bacteria
and biofilm. In particular, we review the types of bacteria and therapeutics used for treatment and the in vitro
and pre-clinical experimental setups employed in sonobactericide research. Mechanisms for ultrasound enhance-
ment of sonobactericide, with a special emphasis on acoustic cavitation and radiation force, are reviewed, and
the potential for clinical translation is discussed. (E-mail: k.lattwein@erasmusmc.nl) © 2019 The Author(s).
Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology. This is an open
access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cide, Ultrasound.INTRODUCTION
In recent decades, the combination of ultrasound and cavi-
tation nuclei has been investigated as an alternative
approach to treatment of several life-threatening diseases.
Ultrasound is a common diagnostic tool and offers several
advantages: it is non-invasive and inexpensive, available
at the point-of-care, and is a safe medical application.
Many different types of cavitation nuclei exist, including
gas or liquid filled and coated or non-coated. These include
micro- and nanobubbles, nanocups, droplets and echogenic
liposomes. When exposed to ultrasound pressure waves,
gas-filled nuclei respond by expanding and contracting
volumetrically, and droplets vaporize into microbubbles.
Microbubble oscillations and acoustic droplet vaporizationddress correspondence to: Kirby R. Lattwein, Thoraxcenter
dical Engineering, Room Ee2302, Erasmus MC, University
l Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The
lands. E-mail: k.lattwein@erasmusmc.nl
1impart theragnostic potential because this characteristic
response can both be detected by clinical diagnostic ultra-
sound scanners and locally enhance treatment by inducing
cellular responses (Sutton et al. 2013; Kooiman et al.
2014, Wang et al. 2018a). “Sonobactericide” describes the
enhancement of bactericidal action aided by ultrasound
and the presence of cavitation nuclei, both endogenous
and exogenous. This terminology is consistent with the
nomenclature of other therapeutic applications of ultra-
sound-activated cavitation nuclei such as sonoporation—
the formation of micropores within cell membranes (Kooi-
man et al. 2014), sonothrombolysis—the lysis of thrombi
(Sutton et al. 2013), sonoreperfusion—the restoration of
perfusion after microvascular obstruction (Black et al.
2016) and sonodynamic therapy—the treatment of neo-
plastic cells using a sonosensitizer (Rosenthal et al. 2004).
Sonobactericide, like the other approaches, can be used
either alone or in combination with other drugs, such as
antimicrobials.
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microbial therapy is limited by the increasing prevalence
of multidrug-resistant bacteria. There are several resis-
tance mechanisms and a large contributing factor is the
development of biofilms, bacterial communities encased
in a complex extracellular polymeric matrix consisting of
variable amounts of numerous constituents, such as poly-
saccharides and proteins. This matrix provides both a
scaffold for antibiotic binding and an anoxic and acidic
environment that can deactivate antibiotics and decrease
bacterial susceptibility via a reduced metabolism (Algburi
et al. 2017). In addition to the presence of a protective
extracellular matrix, the large heterogeneity and general
3-D structure of a biofilm hinder antibiotic delivery, pene-
tration and effectiveness. Additionally, it is difficult to
diagnose bacterial infections before they become exten-
sively established (Grant and Hung 2013; Werdan et al.
2014). Sonobactericide, as illustrated in Figure 1, mayFig. 1. Concept of sonobactericide (not drawn to scale). (a) Pot
bacteria and cavitation nuclei is denoted with a double-heade
microbubbles and activated nanodroplets disrupt bacteria and b
are considered dead or to have compromised membranes becaincrease the “footprint” of antibiotic bactericidal action,
directly kill bacteria and reduce treatment time.
This review focuses specifically on the principles of
sonobactericide using exogenous cavitation nuclei for
potential clinical translation. As this new line of research
gains ground, it is pertinent to establish important consid-
erations for future work. Main concepts of the variability
of bacteria, microbubble composition and acoustic behav-
ior and ultrasound parameters are addressed, and the
experimental setups and measured outcomes are evalu-
ated. Articles on sonobactericide published before August
2019 were identified using PubMed, Web of Science and
Google Scholar search engines with the keywords
“ultrasound,” “microbubble” (or “bubble” or “contrast”)
and “bacteria” or “biofilm.” Sonobactericide articles ref-
erenced by those found in our search were also included.
Articles were excluded if they were not written in English
or if ultrasound alone, that is, without added cavitationential infection environments before ultrasound. Sizing of
d arrow. (b) Ultrasound application in which cavitating
iofilm composition. Bacteria that have become red in (b)
use of the effects from ultrasound and cavitating nuclei.
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a potential application for treatment. For treatment with
ultrasound alone, the reader is referred to other excellent
reviews (Erriu et al. 2014; Cai et al. 2017; Vyas et al.
2019). Twenty-seven sonobactericide articles were
selected for this review (Table 1). One article that investi-
gated microbubbles targeted to biofilm for diagnostic
application (Anastasiadis et al. 2014) and six articles that
studied the effect of cavitation nuclei on bacteria without
ultrasound (Cavalieri et al. 2008, 2012, 2013; Zhou et al.
2012; Mahalingam et al. 2015; Argenziano et al. 2017)
were excluded from Table 1 because these studies did not
meet our definition of sonobactericide.BACTERIA
There exists a vast diversity among bacteria; even
closely related bacteria can have different morphologies,
metabolisms and defenses. Considering shape morphol-
ogy, besides the familiar rod (bacillus), spherical (coccus)
and spiral (twisted) types, at least six other general shapes
exist (Kysela et al. 2016). Though current sonobactericide
research into pathogenic bacteria is dominated by bacil-
lus- and coccus-shaped bacteria, infectious diseases are
also caused by bacteria with other morphologies. Micro-
bubbles may oscillate differently when paired with simi-
larly spherical-shaped Staphylococcus aureus, versus
rod-shaped Escherichia coli or the junction of the kidney-
shaped diplococcus Neisseria meningitidis because of
total surface area contact, tension and rigidity. These
shape differences along with variation in cell surface
could influence treatment success. For example, fimbriae
are bristle-like external filamentous structures protruding
from some bacterial cell surfaces which may create a
stand-off distance between the cavitation nuclei and cell
wall. It has been observed that as the initial stand-off dis-
tance increases, biofilm disruption, sonoporation and cyto-
skeleton disassembly decrease (Goh et al. 2015; Wang
et al. 2018b). Moreover, microbubble dynamics also
depend on the distance from and material properties of a
surface (Overvelde et al. 2011; van Rooij et al. 2017).
Based on the cell envelope (a multilayered structure
on the outside of the cell), almost all bacteria can be sub-
divided into two main groups: Gram+ or Gram. The
cell envelope of Gram+ bacteria consists of a thick
(2080 nm) peptidoglycan layer, which is threaded with
teichoic acid, but lacks an outer membrane, as illustrated
in Figure 2a. Peptidoglycan is made up of repeating units
of muramic acid, which are cross-linked by peptide side
chains. Gram bacteria are covered by a thin peptido-
glycan cell wall (<10 nm), surrounded by an outer lipid
bilayer membrane containing pores, lipoproteins and
lipopolysaccharide (Silhavy et al. 2010), as illustrated in
Figure 2b. It is possible that these structural differencesbetween Gram+ and Gram bacteria will also result in
dissimilar responses to sonobactericide. Several studies
have compared treatment efficacy on both bacteria types
(Mai-Prochnow et al. 2016), including ultrasound (67
and 20 kHz) paired with antibiotics without exogenous
cavitation nuclei (Pitt et al. 1994; Liao et al. 2018), and
observed a markedly different response. Furthermore,
the size of the bacteria (»0.55 mm), whether a single
bacterium, dividing bacterium or aggregates of several
bacteria, and its location (in a suspension, on a surface,
or intracellular) could have an impact on the therapeutic
effectiveness of sonobactericide.
Seemingly subtle differences within a group of
eukaryote cells can affect the differential reaction to
oscillating microbubbles. This variable cell response to
microbubbles is supported by sonoporation studies that
have reported differences in drug delivery efficiency in
two different cancer cell lines (Escoffre et al. 2011). The
top three types of bacteria on which sonobactericide has
been evaluated are (i) Staphylococcus epidermidis
(Gram+, 7 studies, 26%); (ii) S. aureus (Gram+, 6 stud-
ies, 22%); and (iii) E. coli (Gram, 4 studies, 15%)
(Table 1). Methicillin-resistant S. epidermidis was
employed in the majority of the studies (6 out of 7),
whereas methicillin-resistant S. aureus (MRSA) was
used in 4 of the 6 studies. Two research teams used a
green fluorescent protein containing Gram strain
(E. coli, Pseudomonas aeruginosa) (Tandiono et al.
2012; Ronan et al. 2016). The majority of the studies
used only one type of bacteria. Only one study used
mixed types of bacteria (Agarwal et al. 2014). Two
articles compared two different types of bacteria (Zhu
et al. 2013; Li et al. 2015), and another compared a bac-
terium and a fungus (Tandiono et al. 2012). Only four
studies used patient-derived clinical isolates originating
from a central venous catheter (Hu et al. 2018b), infec-
tive endocarditis blood culture (Lattwein et al. 2018),
pneumonia-induced sputum (Fu et al. 2019) and urine
from a patient with lower urinary tract symptoms (Hors-
ley et al. 2019). With the exception of Agarwal et al.
(2014), who used bacteria from a wastewater reclama-
tion plant to investigate membrane biofouling removal,
the other groups used lab-derived strains, which may
limit clinical applicability. Though a laboratory strain
may be deemed wild type, the preparation and (world-
wide) dissemination can lead to genetic changes that
cause both disruption of virulence regulatory pathways,
which often imparts loss of typical in vivo virulence
potential, and phenotypic variation among an entire
strain pedigree (Bæk et al. 2013). Also, typing clinical
isolates, such as staphylococcal protein A (spa) typing
performed by Lattwein et al. (2018) or core-genome
multilocus sequence typing, would aid in the verification
of disease association.
Table 1. Overview of sonobactericide papers
Pathogen
type















Biofilm X - Root canals of single-
rooted polymer and
human teeth
5.25% NaOCl Custom-made 0.032
§ 0.004
N.D. N.D., 1 min Halford et al. 2012
Intracellular X - Infected human bladder
cell organoid model
Gentamicin Custom-made 1.1 2.5 MP 25% duty cycle, PRF
50 Hz, 20 s







X X Eppendorf tube;
intradermally into
mouse ears
Lysozyme Custom-made 1 In vitr 1, 2, 3
W/c In vivo: 3
W/c
50% duty cycle, in
vitro: 1 min; in vivo:
1 min, q.d. for 13 d
Liao et al. 2017
Staphylococcus
aureus
Planktonic X X Tissue culture plate;
bone cement in rabbit
tibiae
Vancomycin SonoVue 1 0.3 W 2 30% duty cycle, 24 h Lin et al. 2015
Biofilm X - Tissue culture plate/
coverslip
Vancomycin Custom-made 1 0.3 W 2 50% duty cycle, 5 min Guo et al. 2017
Biofilm X - Infected clot on a suture
in glass capillaries
Oxacillin Definity 0.12 0.44 M a (PTP) Continuous wave, 50 s
on 30 s off, 30 min
Lattwein et al.
2018







0.08 0.2 W 2 50% duty cycle,
20 min, t.i.d. for 7,
14, 28 d
Zhou et al. 2018
Staphylococcus
epidermidis




Vancomycin SonoVue 0.08 In vitr 1 W/cm2
In vi : 0.5 W/cm2
50% duty cycle, in
vitro: 10 min; in vivo:
20 min, t.i.d. for 72 h
He et al. 2011
Biofilm X - OptiCell Vancomycin Custom-made 0.3 0.5 W 2 or 0.12
MPa
50% duty cycle, 5 min Dong et al. 2013
Biofilm X - OptiCell Vancomycin Custom-made 1 0.5 W 2 or 0.12
MPa
50% duty cycle, 5 min Dong et al. 2017
Biofilm - X Subcutaneously
implanted catheter in
rabbits
Vancomycin Custom-made 0.3 0.5 W 2 or 0.12
MPa
50% duty cycle, 5 min,
b.i.d. for 48 h
Dong et al. 2018
Biofilm X - Tissue culture plate;
glass FluoroDish




Hu et al. 2018b
S. aureus and
S. epidermidis




SonoVue 0.08 1 W/c 50% duty cycle,
10 min
Zhu et al. 2013





SonoVue 0.08 0.2 W 2 50% duty cycle,
20 min, t.i.d. for 48 h
Li et al. 2015
Streptococcus
mutans
Biofilm X - Tissue culture plate
with disk






Biofilm X - Tissue culture plate/
coverslip
Polymyxin B Custom-made 1 3 W/c continuous wave,
5 min
Fu et al. 2019
Chlamydia
trachomatis
Intracellular X - Infected HeLa cells in












Planktonic X - Centrifuge tubes None Albunex; ST68
custom-made
1 500 W m2 1ms pulse, PRF
20 Hz, 5 min
Vollmer et al.
1998
Planktonic X - Tubes Gentamicin SonoVue 0.0465 0.01 W m2 33% duty cycle, 12 h Zhu et al. 2014




























































































N.D. - X Direct injection into
rat prostates
None Custom-made 1 0.5 MPa / 0.023
W/cm2
1% duty cycle, 5 min Yi et al. 2016
N.D. - X Intratracheally infected
mice
Gentamicin Definity 1.3 0.91.2 MPa
(PNP)




Planktonic X - Tissue culture plate None Optison 0.96 0.5 MPa (PPP) 50% duty cycle, PRF
1 Hz, 90 s
Han et al. 2005
Planktonic X - Tissue culture plate None Definity 1 0.25, 0.5, >0.9
MPa (PPP)
050% duty cycle,
PRF 1100 Hz, 10,
90, 450 s
Han et al. 2007
Pseudomonas
aeruginosa




Definity 0.5 1.1 MPa (PNP) 16 cycle tone burst,





Biofilm X - Glass coverslip in
acetate film chamber
None SonoVue 0.25, 1 0.1, 0.5, 0.7 MPa
(PNP)
50 ms pulse Goh et al. 2015
E. coli and Pichia
pastoris
(yeast)
Planktonic X - Microfluidic system None Custom-made 0.13 10 bar (»1 MPa) 50050,000 cycles,
mss, every 5 s
Tandiono et al.
2012
Mixed N.D. Biofilm X - Nylon membrane
surface




US = ultrasound; PRF = pulse repetition frequency; N.D. = not defined; PTP = peak-to-peak pressure; PPP = peak-positive pressure; PNP = peak-negative pressure; q.d. = once daily; b.i.d. = twice daily;
t.i.d. = thrice daily; ISPTA = spatial pulse-average intensity; ISATA = spatial-average temporal-average intensity.
* Calculated peak pressure from ISPTA values obtained by personal communication with author(s). Calculations were performed using the formula (Kinsler et al. 2000) ISPTA = ISATA/duty factor.
y Calculated peak pressure from ISATA values obtained by personal communication with author(s). Calculations were performed using the formula (Kinsler et al. 2000) ISATA = P2/2rc, where



































Fig. 2. Interaction of cavitation nuclei with bacteria: (a) interaction between phospholipid-coated microbubbles and
Gram+ bacteria, (b) interaction between phospholipid-coated nanodroplets and Gram bacteria. PEG = polyethylene
glycol.
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associated with a surface and intracellular. Bacteria in
different growth modes have distinctly different charac-
teristics. Planktonic refers to free living bacterial cells,
which can occur in two forms: as single bacterial cells or
in clusters known as planktonic aggregates (Crosby et al.
2016). Clinically, this planktonic mode generally refers
to bacteria that gain entrance to the human body in the
bloodstream and cause bacteremia, which results in
acute infections often effectively treated by the host
immune system and antibiotics (Stewart and Costerton2001; Brady et al. 2018). Seven sonobactericide studies
(26%) focused on planktonic bacteria (Table 1).
In contrast, bacteria adhering to living (biotic) and
non-living (abiotic) surfaces cover themselves with a pro-
tective matrix, classically known as a biofilm. Bacteria in
a biofilm are protected against attacks from the immune
system and are up to 1000 times more resistant to antimi-
crobial therapy than planktonic bacteria (Lewis 2005).
Biofilm formation is abundant, and an estimated 60% of
human bacterial infections are biofilm related (Costerton
et al. 1999; Fux et al. 2003). Correspondingly, 63%
ARTICLE IN PRESS
Sonobactericide  K. R. LATTWEIN et al. 7(17/27) of the sonobactericide studies focused on treat-
ments for biofilm infections. Biofilm can occur on teeth;
native and prosthetic heart valves; medical implants, such
as prosthetic joints, surgical mesh and screws; pace-
makers; and indwelling catheters (Lebeaux et al. 2014).
These biofilms consist of surface aggregates of bacteria
imbedded in an extracellular matrix of sugars of bacterial
origin, extracellular DNA and proteins, both originating
from either the host or the bacteria. For instance, when S.
aureus is exposed to blood, the coagulation cascade is
activated by coagulase produced by the bacterium. The
fibrin forms a scaffold to which the bacteria bind, facilitat-
ing the formation of a biofilm (Zapotoczna et al. 2016).
Other biofilm composition examples include Pseudomo-
nas aeruginosa forming sputum-encased biofilms sur-
rounded by immune cells in lungs affected by cystic
fibrosis (Maurice et al. 2018), and Proteus mirabilis form-
ing crystalline biofilms by inducing urinary salt precipita-
tion in the catharized urinary tract (Delcaru et al. 2016).
Biofilm extracellular matrix composition and architecture
are complex and highly influenced by species/strain/line-
age, developmental conditions, nutrient availability,
cellcell signaling and interactions with the (host) envi-
ronment (Magana et al. 2018). Moreover, most biofilm
infections are polymicrobial (Short et al. 2014), which
adds to the microenvironment complexity. The various
processes driving bacterial responses are not completely
understood. Thus simulating human in vivo biofilms
remains highly challenging (Bjarnsholt et al. 2013; Rob-
erts et al. 2015).
There are indications that bacteria in a single bio-
film do not behave en groupe. Archer et al. (2011) found
that S. aureus biofilms contain cells in at least four dis-
tinct metabolic states: aerobic, fermentative, dormant
(including very slow growing cells and persisters) or
dead. It is likely that bacterial cells in different metabolic
states, stages of cell division or growth phases will
respond differently to sonobactericide. This hypothesis
is supported by the observation that planktonic bacteria
in stationary growth phase are more resistant to ultra-
sound alone or combined with cavitation nuclei (Vollmer
et al. 1998).
Bacteria can be dispersed from mature biofilms and
become planktonic again (Otto 2008). Dispersal agents,
including chemical, enzymatic and mechanical methods,
can also be used to make biofilm bacteria more suscepti-
ble to therapeutics. Recent literature on P. aeruginosa
suggests that bacteria dispersed from biofilms have a
physiology different from those of both planktonic and
biofilm growth modes (Chua et al. 2014). This difference
suggests a possible transitional growth mode for bacteria
acclimating to the planktonic state. These researchers
found that the dispersed cell phenotype was highly viru-
lent and remained for at least 2 h. This finding issupported further by studies that manipulated biofilm
dispersal, which led to increased disease severity and
progression in mice and a transition from asymptomatic
colonization to active infection, respectively (Connolly
et al. 2011; Marks et al. 2013). Chua et al. (2014) discov-
ered that dispersed cells exhibited lower iron uptake
gene expression and paired the dispersal agent with an
iron chelator, which led to significant reduced viability.
Other work revealed that dispersed bacteria exhibited
increased antibiotic susceptibility and, only after lag
phase (3 h), were more active (Lee et al. 2018). Thus,
biofilm dispersal should be considered and investigated
for sonobactericide development.EXPERIMENTAL APPROACHES
The first to report sonobactericide in combination
with an antimicrobial was Ikeda-Dantsuji et al. in 2011.
Since then, 18 articles on sonobactericide using antimicro-
bials have been published (Table 1). The most studied
clinical antibiotic was vancomycin (7 studies, 26%). Six
other antibiotics were investigated, with different ones for
Gram+ and Gram bacteria except gentamicin. Two
groups investigated two antibiotics separately on the same
bacterial strain. Ikeda-Dantsuji et al. (2011) investigated
one antibiotic to which the Chlamydia trachomatis strain
was susceptible (doxycycline) and one to which this bac-
terial strain was resistant (ceftizoxime). Ronan et al.
(2016) used two aminoglycosides (gentamicin and strep-
tomycin) to which the P. aeruginosa PAO1 strain was
susceptible as determined by CO2 metabolic production.
In addition to the antibiotics, three other antimicro-
bials were investigated: sodium hypochlorite (NaOCl),
lysozyme and human b-defensin 3 (Table 1). The studies
included either clinically appropriate antimicrobials
(dental, NaOCl [Halford et al. 2012]) or antimicrobials
testing a new approach (lysozyme [Liao et al. 2017];
human b-defensin 3, [Zhu et al. 2013, Li et al. 2015,
Zhou et al. 2018]). Sodium hypochlorite is a disinfectant
used widely in endodontic irrigation and health care
facilities (Estrela et al. 2002). Human b-defensin 3, an
endogenous broad-spectrum antimicrobial peptide pro-
duced by various cells in the human body (Dhople et al.
2006), was administered in free form or encapsulated in
liposomes (Zhou et al. 2018). The aim was to load the
liposomes onto SonoVue microbubbles, but proof
thereof was not provided. Lysozyme is a naturally occur-
ring antimicrobial protein and was used in five (non-
sonobactericide) papers as the microbubble coating
material (Cavalieri et al. 2008, 2012, 2013; Zhou et al.
2012; Mahalingam et al. 2015).
All sonobactericide studies used an appropriate
antibiotic targeting a specific microbe, according to ther-
apeutic guidelines (Mandell et al. 2000; Mermel et al.
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et al. 2015; Lanjouw et al. 2016), excluding 2 studies
that could not be linked to guidelines because of nondis-
closure of microbe information beyond species (Lin
et al. 2015) and no disease aim (Zhu et al. 2013). Two
examples of correct antibiotic and microbe pairings are
found in Sugiyama et al. (2018), who aimed to treat
severe Gram bacterial pneumonia and used an E. coli
strain for which the Canadian guideline recommends
gentamicin (Mandell et al. 2000), and Lattwein et al.
(2018), who aimed to treat infective endocarditis and
used a methicillin-susceptible S. aureus isolate for which
both the European (Habib et al. 2015) and American
(Baddour et al. 2015) guidelines recommend oxacillin.
Additionally, of the studies using an antibiotic, 2 of 9
focusing on Gram+ bacteria used strains already resistant
to first-line antibiotics. Many infections are not domi-
nated by resistant microbes, and Gram bacteria can
have higher resistance profiles than Gram+ bacteria (Hu
et al., 2018a). This choice could be influenced by media
coverage, strain access or geographic location. All
articles using vancomycin and methicillin-resistant
microbes originated from China, which has high levels
of reported antimicrobial resistance (Hu et al., 2018a).
A few groups performed sonobactericide using non-
antimicrobial therapeutics. One paper used recombinant
tissue plasminogen activator (rtPA), a clinically
approved fibrinolytic agent, in combination with the
antibiotic oxacillin (Lattwein et al. 2018). Two articles
investigated gene transfection of plasmid DNA into
planktonic bacteria (Han et al. 2005, 2007). The micro-
bubble-mediated accumulation of bone marrow mesen-
chymal stem cells, which can suppress inflammation,
was investigated as a treatment for chronic bacterial
prostatitis (Yi et al. 2016). Although the majority of
sonobactericide studies paired their treatments with ther-
apeutics, 5 (19%) focused directly on the mechanical
and biological effects resulting from ultrasound and
microbubbles alone (Vollmer et al. 1998; Nishikawa
et al. 2010; Tandiono et al. 2012; Agarwal et al. 2014;
Goh et al. 2015).
Many of the in vitro studies were performed in
polystyrene tissue culture well-plates, ranging from 96-
to 6-well plates, for both planktonic and biofilm studies
(10 studies, 37%; Table 1). To the well-plates, Zhu et al.
(2013) added a 10-mm diameter titanium plate (1 mm
thick); Guo et al. (2017) a 13-mm glass coverslip; Fu
et al. (2019) a 12-mm glass coverslip; and Nishikawa
et al. (2010) a polystyrene disk (dimensions not pro-
vided). Two studies also cultured biofilm in a FluoroD-
ish, a 35-mm dish containing a 23.5-mm glass window
(He et al. 2011; Hu et al., 2018b). The geometry of both
these containers could result in the reflection of ultra-
sound at the bottom of the well and at the mediumairinterface. As a result, constructive and deconstructive
interference leading to standing waves could have
occurred (Coakley et al. 1989). Standing waves may also
form within the body, especially in the presence of bone
(O’Reilly et al. 2010). Microbubbles may aggregate at
the nodes of a standing wave (Shi et al. 2013). Increases
in in situ acoustic pressure caused by constructive inter-
ference can cause unwanted bio-effects mediated by
inertial cavitation (Azuma et al. 2005; Deffieux and
Konofagou 2010). The presence of standing waves pro-
duces acoustic field variations that are sensitive to
changes in transducer position, excitation frequency or
temperature (Huber et al. 2011). The acoustic intensity
of the ultrasound field is proportional to the square of the
pressure amplitude when the ultrasound wavelength is
much smaller than the transducer aperture (Kleven et al.
2019). Under the plane wave approximation, the acoustic
pressure is related to the intensity as follows: I = P2/2pc,
where P is the peak acoustic pressure, p is the density
and c is the speed of sound (Kinsler et al. 2000). For
traveling waves, the intensity is a function of time; that
is, once the wave has passed a given spatial location, the
intensity drops to zero. However, for standing waves, the
peak intensity at a spatial location remains constant over
time. Effects of standing wave formation during insona-
tion of cells in different holders have previously been
investigated in detail (Hensel et al. 2011).
Measurement of in situ acoustic parameters is criti-
cal to understanding treatment effects, correlating the
treatment effects to specific outcomes and translating
these to an in vivo setting (ter Haar et al. 2011). Only 5
sonobactericide studies reported calibrating the output in
situ (Tandiono et al. 2012; Goh et al. 2015; Ronan et al.
2016; Lattwein et al. 2018; Horsley et al. 2019). The
lack of standardization of exposure setups makes it diffi-
cult to compare the results in the literature. Reporting
spatial maps of the acoustic field in situ could help
improve the reproducibility and interpretation of in vitro
studies between groups (ter Haar et al. 2011).
In the well-plates and FluorDishes, cavitation nuclei
were administered once for treatment times varying from
20 s to 10 min (see Table 1), with the exception of one
study in which fresh microbubbles were administered
every 4 h for 24 h (Lin et al. 2015). It is unclear whether
microbubbles were still present beyond a few minutes
during insonification because of destruction or dissolu-
tion. For example, Mannaris and Averkiou (2012)
reported that SonoVue microbubbles, insonified in vitro
for 20 ms at 1 MHz using 10 cycle pulses at a pulse repe-
tition frequency (PRF) of 100 Hz, were destroyed and/or
dissolved after only a few pulses at 400 kPa acoustic
pressure, whereas microbubbles were still present after
all pulses at an acoustic pressure of 100 kPa. In addition,
pulses longer than 100 cycles at acoustic pressures >0.4
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oscillation. One group used the OptiCell cell culture sys-
tem for their biofilm experiments (Dong et al. 2013,
2017), which consists of two gas-permeable, thin (75
mm) polystyrene membranes, spaced parallel and 2 mm
apart, providing 50 cm2 area of cell culture. Microbub-
bles were administered once for a 5 min treatment (0.3
or 1 MHz, 0.12 MPa, 50% duty cycle) period.
Several groups used a less commercial in vitro
setup. Goh et al. (2015) used an acetate film square
chamber with the top and right sides each consisting
each of a coverslip and the ultrasound (250 kHz or
1 MHz, 0.11 MPa, 50-ms pulse) transducer positioned
below. One coverslip had a biofilm, such that the micro-
bubbles were either floating beneath the biofilm or
optically trapped at varying distances from the side.
Lattwein et al. (2018) performed sonobactericide under
plasma flow (0.65 mL/min) on biofilms grown statically
on human whole blood clots placed in glass capillaries
(2.15-mm inner diameter). Microbubbles were continu-
ously infused, and ultrasound (120 kHz, 0.44 MPa, con-
tinuous wave, 50 s on 30 s off) was applied
intermittently for 30 min. Ronan et al. (2016) grew bio-
films in a cylindrical flow cell (17 mL/h) with an acousti-
cally transparent membrane on one side and a glass
coverslip on the other, and flow was halted to perform
sonobactericide (0.5 MHz, 1.1 MPa, 16-cycle tone burst,
PRF = 1 kHz) for 5 min, with microbubbles administered
once. Flow was also used by Tandiono et al. (2012) to
treat planktonic bacteria in a microfluidic system com-
posed of polydimethylsiloxane-made channels. In
humans, biofilms can develop in variable fluid flow envi-
ronments depending on the location or under static con-
ditions. Biofilms are highly sensitive to these different
conditions (Thomen et al. 2017). Thus, selection of the
appropriate static or flow condition setting should be tai-
lored to the specific aimed application, such as superfi-
cial skin wound or intravascular device infections.
For dental application, Halford et al. (2012) grew
biofilms in the root canal (12 mm length) of single-
rooted extracted human teeth under constant agitation
(120 rpm). Microbubbles were delivered into canals and
insonified with a P5 Newtron dental ultrasonic hand
piece (28 to 36 kHz ultrasound) for 1 min. Horsley et al.
(2019) employed a bladder organoid model using a mod-
ified acoustically compatible chamber (Carugo et al.
2015). Briefly, a polycarbonate filter insert (12 mm
diameter) cultured with infected human bladder cells
was fixed between an Ibidi culture dish (35 mm) and a
polydimethylsiloxane lid. Cavitation nuclei were added,
and the dish and lid were coupled and then insonified
(1.1 MHz, 2.5 MPa, 5500 cycles, 20 ms pulse duration)
for 20 s. Other in vitro experimental setups were on
nylon membranes (47 mm diameter, pore size = 0.2 mm)and in centrifuge tubes (2 and 5 mL) (Table 1). Nylon
membrane biofilms were treated in a beaker placed in a
sonicator (0.042 MHz, on for 2 s every 2 min) while
microbubbles were continuously introduced for 15 min
(Agarwal et al. 2014). The planktonic bacteria in tubes
were treated (1 MHz, 500 W/cm2, 2% duty cycle) for
5 min (Vollmer et al. 1998) or 12 h (0.0465 MHz, 0.01
W/cm2, 33% duty cycle) (Zhu et al. 2014) and in Eppen-
dorf tubes (1 MHz, 13 W/cm2, 50% duty cycle) for
1 min (Liao et al. 2017), all with a one-time administra-
tion of microbubbles.
Three in vitro studies were followed up with a cor-
responding in vivo study in the same article (He et al.
2011; Lin et al. 2015; Liao et al. 2017). Thirty percent of
the articles on sonobactericide (8/27) have investigated
therapeutic efficacy in pre-clinical animal models
(Table 1). Four groups chose to emulate implanted medi-
cal device infections using subcutaneous implants, near
the spine, with biofilm grown on catheter pieces or poly-
ethylene disks in rabbits (He et al. 2011, Dong et al.
2018) and titanium plates in mice (Li et al. 2015; Zhou
et al. 2018). Microbubbles were injected subcutaneously
into the implant area before ultrasound. For each of the
three ultrasound exposures (20 min) per day, He et al.
(2011) injected 200 mL of microbubbles (2£ 108 to
5£ 108/mL) every 5 min, and both Li et al. (2015) and
Zhou et al. (2018) injected 30 mL once, 2£ 108 to
5£ 108/mL and concentration not disclosed, respec-
tively. Dong et al. (2018) applied ultrasound twice a day
for 5 min, and injected 500 ml (1.2£ 109/mL diluted to
1% v/v) each time. All studies used a 50% duty cycle.
However, acoustic parameters, treatment intervals and
duration times varied (Table 1).
Lin et al. (2015) investigated the ability of sonobac-
tericide to increase the elution rate of antibiotics from
vancomycin-loaded bone cement in a periprosthetic
infection rabbit tibia model. Ultrasound (1 MHz, 0.3 W/
cm2, 30% duty cycle) was applied transcutaneously for
24 h, and microbubbles (2£ 108 to 5£ 108/mL) were
injected into the same space as the S. aureus bacteria at
four time points. Surrounding tissues were evaluated
directly after treatment. For chronic bacterial prostatitis
modeled in rats, Yi et al. (2016) used sonobactericide to
induce accumulation of bone marrow mesenchymal
stem cells to reduce inflammatory reactions and resolve
infection. After 4 wk of infection induction with E. coli,
microbubbles (0.1 mL/kg) were directly injected into
prostates and insonified (1 MHz, 0.5 MPa, 1% duty
cycle) for 5 min. Afterward, stems cells (1£ 107) were
administered intravenously, and therapeutic effective-
ness was evaluated after 24 h and 2 wk.
Another study focused on harnessing sonobacteri-
cide in a model of severe bacterial pneumonia with the
goal of enhancing antibiotic delivery to infected lung
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administered intratracheally, and 6 h later gentamicin
was injected intraperitoneally. After 30 min, microbub-
bles (1£ 109) were intravenously administered and
ultrasound (1.3 MHz, 0.91.2 MPa, pulse every 5 s;
pulse duration not specified) was transmitted thoracically
for 5 min. Lavage and tissues samples were evaluated at
30 min and 2 h, respectively, after ultrasound applica-
tion. Liao et al. (2017) also used mice and aimed to
improve acne vulgaris treatment using transdermal sono-
bactericide with lysozyme-shelled microbubbles. Ears
were infected intradermally with Propionibacterium
acnes. Gel loaded with lysozyme microbubbles was
placed on top of the infected area and insonified (1 MHz,
3 W/cm2, 50% duty cycle) daily for 1 min. Effectiveness
was assessed at several time points during the 13 d of
treatment.
Various techniques were used for assessing sonobac-
tericide efficacy. The colony-forming unit plate-counting
method was utilized to determine antimicrobial efficacy
(14/27, 52%), for some in vitro and all except one in vivo
study (Yi et al. 2016). Bacterial plating is relatively easy
to perform and considered the “gold standard” for deter-
mining viable bacteria counts. This technique, however, is
widely known to underestimate the absolute number of
bacteria. Another potential limitation is that often to
obtain post-treatment samples, biofilms have been
mechanically disrupted, scraped, centrifuged, digested,
vortexed or sonicated, which might have induced micro-
bial alterations. Several articles employed histopathologic
staining, either crystal violet or hematoxylin and eosin, to
observe bacterial morphology (macroscopy and light
microscopy), quantify biofilm density by absorbance lev-
els in a microplate reader or compare inflammatory
effects over time. This method can be used for high-
throughput screening, but it does not discriminate between
live and dead cells. Immunohistochemistry was used by
Yi et al. (2016) to quantify inflammatory cytokineFig. 3. Bright-field micrographs of in vitro-produced Staphyloc
(a) plasma alone; (b) plasma, recombinant tissue plasminogen
and (c) plasma, rt-PA, oxacillin, ultrasound and Definity (mic
(beige). The thick black line, seen in all images and denoted by
infected clots were adhered. Ultrasound parameters were 0.12
(50 s on, 30 s off) continuous waves for 30 min. Adaptexpression and distribution. Agarwal et al. (2014) desic-
cated their mixed species biofilms to determine fixed bio-
mass for overall density quantification and also, albeit
with additional steps, for extracellular protein and poly-
saccharide content.
Several microscopic techniques were utilized for
visualization of treatment, including light, epifluores-
cence, confocal laser scanning and transmission and
scanning electron microscopy. Light microscopy was
combined with or without time-lapse and high-speed
camera observations (Halford et al. 2012; Tandiono
et al. 2012; Goh et al. 2015; Lattwein et al. 2018); see
Figure 3 for a light microscopy example. Fluorescence
detection, with either a widefield or a confocal micro-
scope, was the most frequently utilized optical imaging
modality for qualitative and quantitative visualization of
live and fixed cell populations (16/27, 59%). These
images can provide information not only on viability,
but also biomass, average biofilm thickness and struc-
tural heterogeneity. Live/dead nucleic acid staining with
Syto 9 (viable cells) and propidium iodide (dead or
membrane-disrupted cells) were often used and the cells
were observed with confocal microscopy (Fig. 4) to
assess biofilm populations. Note that biofilm nucleic
acid fluorescence signals might not only indicate a single
bacterium, but also extracellular DNA found throughout
many biofilms (Okshevsky and Meyer 2014). To investi-
gate biofilm compositional changes, extracellular pro-
teins were stained with fluorescein isothiocyanate
(FITC), lipids with Nile red and a- and b-polysacchar-
ides with lectin concanavalin A conjugated with tetra-
methyl rhodamine and fluorescence brightener,
respectively (Agarwal et al. 2014). These polysacchar-
ides (a, b) can also be visualized with FITC-conjugated
lectin concanavalin A and wheat germ agglutinin (Anas-
tasiadis et al. 2014). Scanning and transmission electron
microscopy was used for post-treatment ultrastructural
observations of planktonic bacteria and biofilmoccus aureus-infected clots after a 30-min treatment with
activator (rt-PA, thrombolytic) and oxacillin (antibiotic);
robubble). The black arrow in (a) indicates the biofilm
a white arrow in (a), is the suture to which the respective
MHz and 0.44 MPa peak-to-peak pressure, intermittent
ed, with permission, from (Lattwein et al. 2018).
Fig. 4. Confocal laser scanning micrographs of in vitro, propidium iodide (red)-stained Pseudomonas aeruginosa PAO1:
gfp-2 biofilms after treatment with (a) nothing (control); (b) ultrasound and Definity (microbubbles); (c) gentamicin
(antibiotic) alone; and (d) gentamicin, ultrasound and Definity. Top: Top-down maximum intensity projection. Bottom:
Corresponding 3-SD volume rendering. Ultrasound parameters were 0.5 MHz at 1.1 MPa peak negative pressure with a
16-cycle tone burst and pulse repetition frequency of 1 kHz for 5 min. Reprinted, with permission, from Ronan et al.
(2016).
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copy (Fig. 5) was also used to complement confocal find-
ings (Dong et al; 2013, Zhu et al. 2013; Li et al. 2015;
Guo et al. 2017; Dong et al. 2018; Zhou et al. 2018). For
transmission microscopy, sample preparation of biofilms
required removal from culture plate; thus, the biofilms
were mechanically scraped, which could alter cellular
structure (Hu et al., 2018b).
Genetic testing was performed in 7 studies, using
the polymerase chain reaction (PCR) method (Han et al.
2005, 2007; Tandiono et al. 2012; Zhu et al. 2013; Li
et al. 2015; Yi et al. 2016; Dong et al. 2017; Zhou et al.
2018). PCR was used to investigate the impact of sono-
bactericide on (i) the expression of genes (Zhu et al.
2013; Li et al. 2015; Dong et al. 2017; Zhou et al. 2018)
and mRNA (Yi et al. 2016); (ii) the successful incorpo-
ration of a gene (Han et al. 2005, 2007); and (iii) the sta-
tus of genes up- and downstream after incorporation
(Han et al. 2005). PCR was also used to quantifyFig. 5. Scanning electron micrographs of Staphylococcus epide
in rabbits after treatment with (a) nothing (control); (b) ultra
(antibiotic) alone; and (d) vancomycin, ultrasound and custom
Ultrasound parameters were 0.3 MHz and 0.5 W/cm2 (or 0.12
twice daily) Adapted, with permissintracellular DNA released into the supernatant after
treatment, which provided an indication of disrupted
(lysed) cells (Tandiono et al. 2012). With respect to its
advantages, PCR is not technically demanding and is
fast and highly sensitive. High sensitivity is also a disad-
vantage concerning contamination; in addition, the spe-
cific target of interest must already be known, and
caution should be taken in interpreting the results
because of the potential for extracellular DNA released
from bacteria not triggered by lysis. Two studies investi-
gating intracellularly infected mammalian cells evalu-
ated cytotoxicity in response to therapy using a trypan
blue exclusion test (Ikeda-Dantsuji et al. 2011) and a lac-
tate dehydrogenase assay (Horsley et al. 2019).
Changes in biofilm metabolism, in response to dif-
ferent treatments, were measured by confocal imaging
with 5-cyano-2,3-ditolyltetrazolium chloride dye (Hu
et al., 2018b), a CO2-evolution monitoring system
(Ronan et al. 2016) or an absorbance-based resazurinrmidis biofilms from catheters subcutaneously implanted
sound and custom-made microbubbles; (c) vancomycin
-made microbubbles. Original magnification: £ 2000).
MPa) with a 50% duty cycle for a total of 20 min (5 min
ion, from Dong et al. (2018).
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gation of cellular metabolism provides an indication of
the overall bio-effect, the growth rate, biomass, cell via-
bility and persister development could not be specified.
Vollmer et al. (1998) and Yi et al. (2016) used biolumi-
nescence as an indicator of bacterial cell stress responses
and the distribution of stem cells in rats, respectively.
Besides using fluorophore internalization, one group
used a fluorescence polarization immunoassay to deter-
mine the amount of vancomycin eluted from bone
cement after in vitro treatments (Lin et al. 2015). An
enzyme-linked immunosorbent assay was also used after
treatments to determine levels of gentamicin (Sugiyama
et al. 2018) and inflammatory cytokines (Yi et al. 2016)
in tissue. Both immunoassays are highly specific, even
in samples with protein content such as serum (Yu et al.
2010; Odekerken et al. 2015), and are commercially
available for various antibiotics on the market.CAVITATION NUCLEI FOR
SONOBACTERICIDE
Cavitation nuclei are a key part of sonobactericide
because their volumetric changes in response to an ultra-
sound field induce bio-effects. From the commercially
available cavitation nuclei, SonoVue was used most
often (8 studies, 30%). SonoVue (available as Lumason
in the United States, approved by the U.S. Food and
Drug Administration [FDA] in 2016) consists of SF6 gas
microbubbles (mean diameter: 1.52.5 mm, 99% of
microbubbles 10 mm) stabilized by a lipid coating
(Schneider et al. 1995). SonoVue/Lumason is approved
for clinical diagnostic use in several countries worldwide
(Nolsoe and Lorentzen 2016). Other commercially avail-
able lipid-coated microbubbles have also been used for
sonobactericide studies, namely, Definity (4 studies,
15%, (octafluoropropane (C3F8) gas core; mean diameter
1.13.3 mm; 98% of microbubbles <10 mm) (Definity
2011) and Sonazoid (1 study, 4%, C4F10 gas core; mean
diameter 2.1 mm§ 0.1; <0.1% of microbubbles larger
than 7 mm) (Sontum 2008). Definity and Sonazoid are
approved for clinical diagnostic use in several countries
worldwide (Nolsoe and Lorentzen 2016). Note that
Albunex, used by Vollmer et al. (1998), was the first
commercially available ultrasound contrast agent (in
1992), with a mean microbubble diameter of 3.8 mm
(98.8% of microbubbles <10 mm), an air core and a
human albumin coating (Feinstein 1989). However,
Albunex is no longer available (Mayer and Grayburn
2001). Optison is another human albumin-coated micro-
bubble (C3F8 gas core, mean diameter: 3.04.5 mm;
95% of microbubbles <10 mm; FDA approved in 2012)
and approved for clinical use in the United States and
Europe. Vollmer et al. (1998) also used custom-mademicrobubbles (ST68, mean diameter: 3.8 mm, air core,
coating mixture of surfactants Span 60 and Tween 80
[Forsberg et al. 1997]) in their study.
The advantage of using commercially available cavi-
tation nuclei is that their response to ultrasound has been
thoroughly characterized (Gorce et al. 2000; Moran et al.
2002; Chen et al. 2003; Chetty et al. 2008; Guidi et al.
2010; Faez et al. 2011; Helfield and Goertz 2013). In addi-
tion, these cavitation nuclei are sterile with minimal
batch-to-batch variability. On the other hand, custom-
made cavitation nuclei as used in 11 of the sonobacteri-
cide studies can offer advantages, such as targeting by
incorporating a ligand in the coating and drug loading.
Although there are several types of targeted micro-
bubbles for ultrasound molecular imaging and drug-
loaded microbubbles for ultrasound-mediated drug deliv-
ery, or a combination thereof (Sutton et al. 2013; Kooi-
man et al. 2014; van Rooij et al. 2015), so far only one
study has employed microbubbles targeted to S. aureus
biofilms in vitro using a monoclonal immunoglobulin
antibody to protein A or a lectin from P. aeruginosa for
ultrasound molecular imaging (Anastasiadis et al. 2014).
These targeted microbubbles were found to bind to the
biofilm matrix in proportion to the surface area.
A few studies have reported on drug-loaded micro-
bubbles or droplets for treatment of bacterial biofilms.
Horsley et al. (2019) conjugated custom-made gentami-
cin-loaded liposomes onto microbubbles (ratio 1:5)
using biotinavidin bridging (mean diameter: 5.79 §
1.53 mm). The microbubbles had a gas core of SF6 and
the lipid coating consisted of 1,2-distearoyl-sn-glycero-
3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-carboxy(poly-ethylene glycol)
(DSPE-PEG(2000)), DSPE-PEG-biotin and 1,2-dipalmi-
toyl-sn-glycero-3-phosphoethanolamine-N-(lissamine
rhodamine B sulfonyl) (ammonium salt) (Rod-PE) in a
molar ratio of 79.5:10:10:0.5. The protein lysozyme was
used as the drug and also formed the coating of micro-
bubbles. One study custom-made these microbubbles
with an air gas core (mean diameter of 4 § 1 or 6 § 2
mm, depending on the duration of protein denaturation:
15 and 2 min, respectively) (Cavalieri et al. 2008; Zhou
et al. 2012), and another used C3F8 (mean diameter:
2.52.9 mm, depending on the sonication power) (Liao
et al. 2017). Lysozyme-coated microbubbles loaded with
either spherical bovine serum albumin-coated gold nano-
particles (4.5 nm in diameter) or polyvinylpyrrolidone-
coated gold nanoparticles (15 nm in diameter) were also
produced by Cavalieri et al. (2013). Both types of gold
nanoparticles had no effect on microbubble size distribu-
tion or stability. Mahalingam et al. (2015) produced poly
(vinyl alcohol)-lysozyme-coated microbubbles (10250
mm, nitrogen gas core) loaded with gold nanoparticles
(average diameter: »10 nm). These microbubbles were
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without them, which is in contrast to what Cavalieri
et al. (2013) found. The difference in the type of coating
or microbubble size could be the reason for the differ-
ence in stability.
Nanodroplets that can be phase-transitioned into
microbubbles using ultrasound, a phenomenon known as
acoustic droplet vaporization (Kripfgans et al. 2000; Lin
and Pitt 2013), have been loaded with the antibiotic van-
comycin by Argenziano et al. (2017). The nanodroplets
(average diameter »300 nm) had a core of perfluoropen-
tane and shell of lipid and dextran sulfate to which the
vancomycin was coupled by electrostatic interaction.
The authors sterilized their formulation using ultraviolet
light. The nanodroplets (mean diameter: 309 nm) made
by Guo et al. (2017) consisted of a core of perfluoropen-
tane and a coating of lipids. Microbubbles (mean diame-
ter: 1.5 mm) containing a C3F8 gas core and coating of
the same lipids were also produced.
Four groups produced custom microbubbles for co-
administration with an antibiotic (Ikeda-Dantsuji et al. 2011;
Dong et al. 2013, 2017, 2018), an antibiotic encapsulated in
a liposome (Fu et al. 2019) or stem cells (Yi et al. 2016).
Dong et al. (2013, 2017, 2018) produced lipid-coated micro-
bubbles with a gas core of C3F8 and diameter of 46 mm.
The coating consisted of the lipids DSPC and 1,2-dipalmi-
toyl-sn-glycerol-3-phosphate-ethanolamine at a molar ratio
of 66:34. The microbubbles were sterilized by 60Co irradia-
tion. Ikeda-Dantsuji et al. (2011) produced microbubbles
(»1 mm) encapsulating C3F8 gas and coated with DSPC
and DSPE-PEG(2000), at a molar ratio of 94:6. Microbub-
bles (mean diameter: 2.39 § 0.05 mm) with a coating of
1,2dipalmitoylsnglycero3phosphocholine, DSPE
and cholesterol, mass ratio of 10:4:1 and a C3 F8 gas core
were produced by Fu et al. (2019). A thorough characteriza-
tion of the response of these microbubbles to ultrasound was
not reported in these publications. The lipid-coated micro-
bubbles (1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol,
DSPC and PEG4000 at a mass ratio of 30:30:3000 w/w)
with a C3F8 gas core (mean: 2 mm) made by Yi et al. (2016)
were compared with SonoVue for liver imaging (Liu et al.
2011). Enhancement was similar but persisted longer (still
present 6 min 30 s after injection) for these custom-made
microbubbles.
In the study by Halford et al. (2012), microbubbles
were produced during ultrasound treatment (2836
kHz) from a solution containing perfluorodecahydro-
naphthalene as oxygen carrier; 30% hydrogen peroxide,
or H2 O2, as oxidizer; and the non-ionic detergent surfac-
tant Triton X-100 as shell stabilizer. The figure of the
formed microbubbles indicates microbubble diameters
on the order of 200 mm. Non-coated microbubbles were
also produced during ultrasound treatment (130 kHz) in
the study by Tandiono et al. (2012). In another study,non-coated microbubbles with a mean size of 510 mm
were produced with a microbubble generator (Agarwal
et al. 2014). No specifics on the gas core and microbub-
ble coating were provided.
The synergy between microbubbles and ultrasound
exposure parameters is important for sonobactericide
because the radial pulsation of microbubbles may
increase the “footprint” of bactericidal action and reduce
treatment times. The oscillation of each microbubble
depends highly on its resonance behavior, that is, the
ultrasound frequency at which the amplitude of oscilla-
tion is largest. In general, the resonance frequency is
inversely related to the microbubble diameter, but the
properties of the microbubble coating also play a role as
rigid microbubble coatings increase the resonance fre-
quency (Leighton 1994; Kooiman et al. 2014). Interest-
ingly, 78% (21/27) of sonobactericide studies used
lipid-coated microbubbles (see Table 1). A small frac-
tion of the commercially available microbubbles are res-
onant for a particular insonification scheme because of
the polydisperse population (Hettiarachchi et al. 2007).
Different ultrasound center frequencies were used for
sonobactericide, including frequencies used in clinical
diagnostic imaging (1 MHz, 13 studies, and 1.3 MHz, 1
study; see Table 1). At these frequencies, only a subpop-
ulation of the microbubbles are expected to oscillate in
resonant modes. The ultrasound frequency employed in
the other studies was lower, namely, 500 kHz (1 study),
on the order of 300 kHz (4 studies), 120130 kHz (2
studies) or between 28 and 80 kHz (7 studies). For these
very low ultrasound frequencies, only microbubbles sub-
stantially larger than 10 mm in diameter would have
been at resonance. Gas from the microbubbles was likely
liberated and coalesced and grew by rectified diffusion
in the acoustic field until the microbubbles reached reso-
nant size (Postema et al. 2002; Bader et al. 2015).
Another important consideration for microbubble oscil-
lation is the viscosity of the surrounding medium and
confinement because oscillations are damped when the
viscosity increases or when microbubbles are confined
(Kooiman et al. 2014). For the in vivo studies, the micro-
bubbles were confined in tissue as a result of injection
into the area of the implanted catheter (Dong et al.
2018), dish (He et al. 2011), titanium plate (Li et al.
2015) or tibial canal (Lin et al. 2015). It appears that
these studies did not consider the effect of attenuation of
ultrasound by overlying tissue.EXPERIMENTAL OUTCOMES
All sonobactericide studies have reported an
enhanced effect beyond that of antibiotics alone. The
goal of all of these studies was proof-of-principle and
the approaches used generally differed. Directly
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large variability between them. Differences between the
groups include the bacteria used and the different growth
conditions, ultrasound parameters, cavitation nuclei and
experimental setups. Nevertheless, this section aims to
provide a discussion and make general comparisons
between the experimental outcomes.
Ultrasound interacts with tissue by heating (ter Haar
2010), radiation force (Nyborg 1953) and cavitation-based
mechanisms (Dalecki 2004; ter Haar 2009). Heating and
radiation force could enhance the effect of antibiotics
(Hajdu et al. 2010), increasing membrane permeability
(Juffermans et al. 2006) and cell detachment, respectively.
Cavitation is an important mechanism for sonobactericide.
Stable cavitation involves gentle oscillations of microbub-
bles (Bader and Holland 2013), and inertial cavitation
denotes the rapid growth and rapid collapse of microbub-
bles (Holland and Apfel 1989). The acoustic pressure
required to initiate inertial cavitation can be higher than
the pressure required for stable cavitation (Bader and Hol-
land 2013) and also depends on fluid properties and the
cavitation nuclei (Apfel 1997). Inertial cavitation forms
microjets (Ohl et al. 2015) that can damage or deform the
biofilms (Goh et al. 2015). Administration of cavitation
nuclei can reduce the cavitation threshold (Bader and Hol-
land 2013).
When microbubbles oscillate in an ultrasound field,
fluid flow is generated around the microbubbles (Elder
1959; Leighton 1994). This phenomenon is known as
microstreaming. The effects of microstreaming are
prominent when the oscillating bubble is located near a
boundary and when it is excited at resonance (Leighton
1994). Microstreaming can cause bio-effects by promot-
ing fluid transport and producing shear stresses on cells
(Collis et al. 2010). Microbubble destruction in response
to ultrasound can occur through either acoustically
driven diffusion or microbubble fragmentation (Chomas
et al. 2001). Fragmentation in response to ultrasound
exposure is typically associated with inertial cavitation
(Shi et al. 2000) and can produce mechanical bio-effects.
Table 1 indicates that the majority of sonobacteri-
cide studies used one pressure amplitude, or acoustic
intensity, and one center ultrasound frequency. Four
studies tested multiple pressures/intensities (Han et al.
2007; Ikeda-Dantsuji et al. 2011; Goh et al. 2015; Liao
et al. 2017), and one employed two frequencies (Goh
et al. 2015). Ikeda-Dantsuji et al. (2011) reported that a
higher ultrasound intensity (0.44 W/cm2) further
increased sonobactericide efficacy above that of doxycy-
cline alone by approximately three times that of the
lower intensity setting (0.15 W/cm2). However, when
another antibiotic (ceftizoxime), to which C. trachomatis
is resistant, was employed, they found that the higher
ultrasound intensity only slightly improved thetherapeutic efficacy further. Liao et al. (2017) found that
higher-intensity insonification (2 and 3 W/cm2) beyond
1 W/cm2 did not further enhance sonobactericide. Han
et al. (2007) also found that as the acoustic pressure
increased (0.25, 0.5, >0.9 MPa), delivery of their model
drug into bacteria correspondingly increased.
Other ultrasound parameters were explored, such as
PRF (0100 Hz), duty cycle (5 and 50%), concentration
of cavitation nuclei (0, 3.3, 10, 33% v/v) and exposure
duration (0, 10, 90, 450 s) (Han et al. 2007). An increase
in efficacy was seen with corresponding increased
parameters, except PRF, which had no increased effect.
As desired, bacterial viability was not affected among
the parameters tested by Han et al. (2007) for the crea-
tion of an recA-positive strain of Fusobacterium nuclea-
tum. recA renders bacteria more sensitive to ultraviolet
light and reportedly repairable sonoporation (Han et al.
2007). By using similar sonobactericide conditions also
on planktonic, exponential growth phase, Gram bacte-
ria, albeit with E. coli, Vollmer et al. (1998) observed
bacterial death (up to 49.7 § 6.2%) and activation of
stress-response genes.
Goh et al. (2015) used high-speed optical imaging
to investigate the impact of cavitating microbubbles on
biofilm surfaces. At 0.1 MPa (1 MHz, 50-ms pulse),
microbubble oscillation was reported to be small, and
caused minimal biofilm disruption. At a higher pressure
(0.7 MPa, 1 MHz, 50-ms pulse), a 7.4-mm SonoVue
microbubble had an extremely large radial excursion
(Rmax = 27.3 mm) with a liquid jet within that led to
mechanical dislodgement of the bacteria from the bio-
film. The direction of a jet with respect to the surface of
the biofilm depends on the elasticity of the surface (Ohl
et al. 2015). Accordingly, jet formation can create sub-
stantial shear force leading to either an indentation or an
invagination of the surface (Chen et al. 2011, 2012).
Although Goh et al. (2015) used two ultrasound frequen-
cies (0.25 and 1 MHz), they applied each frequency in a
different setup (biofilm horizontally or vertically posi-
tioned). Therefore, the effects of the different frequen-
cies could not be compared. They found that ultrasound
parameters and the distance between the biofilm surface
and the cavitating microbubbles affected the efficacy of
biofilm disruption. Ultrasound alone did not disrupt the
biofilm structure. As the initial distance between the
microbubble and the biofilm increased, the disruption
efficacy decreased. This observation provides support
for the use of biofilm-targeted microbubbles to increase
the efficacy of sonobactericide.
Ronan et al. (2016) also described biofilm disrup-
tion, in the form of craters, after ultrasound and micro-
bubble exposure without antibiotics (Fig. 4). If bacteria
are forcibly released from biofilms by microbubble oscil-
lations, as suggested by several studies including Ronan
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status of these dispersed cells after treatment need to be
assessed. Sonobactericide could be combined with cur-
rent “traditional” or other new antimicrobials to reduce
the spread of or eliminate altogether transitional dis-
persed cells that may be more virulent. Planktonic bacte-
ria are often sensitive to antibiotics at much lower
concentrations than are the same bacteria in biofilms
(Olson et al. 2002). Thus, liberation of bacteria into the
bloodstream after sonobactericide is not necessarily
anticipated to pose additional risks.
Inertial cavitation caused by ultrasound-mediated
microbubble destruction can produce defects in the bio-
film matrix, aiding the penetration of antibiotics (He
et al. 2011). Microbubbles and ultrasound exposure have
been reported to increase the elution of an antibiotic
from polymethylmethacrylate cement and increase the
efficacy of bactericidal treatment in vitro and in vivo
(Lin et al. 2015). Ultrasound-mediated microbubble
destruction can also increase the metabolic activity of
the bacteria in the biofilm, making it responsive to treat-
ment with antibiotics (Hu et al., 2018b). However,
Ronan et al. (2016) reported a decrease in biofilm metab-
olism, by analyzing carbon dioxide production, after
either antibiotic alone or antibiotic combined with ultra-
sound and microbubbles. Because of the experimental
setup, it could not be definitively determined if the
decrease was from growth rate or biofilm mass reduc-
tion, and is speculated to be both. Although bacteria can
develop resistance to antimicrobials over time through
genetic alterations, ultrasound acts without allowing
these organisms to adapt to the physical stresses
(Vollmer et al. 1998). Additionally, Zhou et al. (2018)
found in vivo that expression of the MecA gene responsi-
ble for encoding resistance to b-lactam antibiotics in
MRSA was significantly reduced in the sonobactericide
group with human b-defensin 3, more than twice that of
the antimicrobial alone.
It has been postulated that bacterial cells could be
more susceptible to sonobactericide because of their rigid
cell membranes, which contrasts with the compliant phos-
pholipid bilayers of mammalian cells that may resist rup-
ture owing to ultrasound exposure (Conner-Kerr et al.
2010). When ultrasound is combined with cavitation
nuclei and an antibiotic, sonobactericide efficacy can be
enhanced, as illustrated by the in vitro and in vivo studies
in this review. For example, in vitro studies reported by
Dong et al. (2013) utilized Sonovue and reduced colony-
forming units of S. epidermidis eightfold relative to treat-
ment with vancomycin and ultrasound (1-MHz frequency,
0.5-W/cm2 intensity, 50% duty cycle, 5 min). In in vivo
studies, findings of enhanced bacterial killing when sono-
bactericide included an antimicrobial were also reported;
for example, Sugiyama et al. (2018) observed an almost1-log reduction in colony-forming units compared with
all controls. Sonobactericide could produce equivalent
therapeutic effects at a lower antibiotic dose, which may
reduce complications associated with systemic toxicity,
especially renal and liver complications. Sonobactericide
may increase antibiotic (and other therapeutics) cytotoxic-
ity; Horsley et al. (2019) reported higher toxicity in
human urothelial cells with ultrasound-exposed solutions
of microbubbles coated with liposomes containing genta-
micin at 2.64 and 5.28 mg/mL than free gentamicin at the
much higher clinically approved dosage (200 mg/mL).
This finding highlights that cytotoxicity should be more
widely considered as a sonobactericide test parameter in
future studies.
In addition to Han et al. (2007), the microbubble
dose dependence of sonobactericide has been investi-
gated by three other groups that found an increase in the
efficacy of sonobactericide with increasing concentration
of microbubbles (Ikeda-Dantsuji et al. 2011; Dong et al.
2013, 2017), indicating dose-dependent synergy. Only
Han et al. (2007) used more than two concentrations,
with which a near-linear trend between microbubble
concentration and treatment efficacy could be observed.
A similar increase in bio-effects with increasing micro-
bubble concentration has been reported for sonoporation
of eukaryotic cells (Ward et al. 2000) and bloodbrain
barrier disruption (Song et al. 2017). Increasing the anti-
biotic concentration also resulted in an increasing dose-
effect relationship for all treatments of Acinetobacter
baumannii, including microbubbles combined with free
polymyxin B and microbubbles combined with free chi-
tosan-modified polymyxin B-loaded liposomes (Fu et al.
2019). Horsley et al. (2019) increased both antibiotic
and microbubble concentrations, because gentamicin
was encapsulated on liposomes bound to the microbub-
bles, which led to an enhanced reduction of bacterial
load in infected urothelial cells.
The “in vial” concentration of Definity is 4.2£ 109
microbubbles/mL, that of Albunex 7£ 108 microbub-
bles/mL (Christiansen et al. 1994) and that of SonoVue/
Lumason 3.0£ 108 to 1.1£ 109 microbubbles/mL.
Assuming a blood volume of 5 L in an average human,
the in vivo concentrations for Definity, Albunex and
Lumason correspond to 8.4£ 105/mL, 1.4£ 105/mL and
6£ 104 to 2.2£ 105/mL, respectively. Several sonobac-
tericide studies reported thus far have used high concen-
trations of microbubbles (107 to 108/mL) both in vitro
(Vollmer et al. 1998; Dong et al. 2013, 2017; Hu et al.,
2018b) and in vivo (He et al. 2011; Li et al. 2015; Dong
et al. 2018), relative to the concentrations currently used
in clinical diagnostic imaging. This approach could
potentially be employed in non-vascular applications
such as dental, skin wound and implant biofilms (He
et al. 2011, Li et al. 2015, Dong et al. 2018).
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and rodent models suggest that high concentrations of
microbubbles administered intravenously, up to
250 times higher than the clinical dose, may be well tol-
erated (Schneider et al. 2011). Although in vitro studies
have indicated that large microbubbles (»0.3 mm) can
destroy biofilms under flow by microbubble collision
(Sharma et al. 2005; Parini and Pitt 2006), this mecha-
nism is unlikely to occur for microbubbles of clinically
relevant sizes for vascular applications (i.e., 110 mm).
Five studies used custom-made lysozyme-coated
microbubbles in the absence of ultrasound (Cavalieri
et al. 2008, 2012; Zhou et al. 2012; Cavalieri et al. 2013;
Mahalingam et al. 2015). These exhibited antimicrobial
properties on Micrococcus lysodeikticus, S. aureus and
E. coli. Lysozyme-coated microbubbles, or poly(vinyl
alcohol)-lysozyme-coated microbubbles, loaded with
gold nanoparticles were found to have a stronger antimi-
crobial effect than non-loaded microbubbles on plank-
tonic Micrococcus lysodeikticus (Cavalieri et al. 2013)
and E. coli (Mahalingam et al. 2015). The coated gold
nanoparticles alone lacked lytic activity in the Cavalieri
study, and thus the authors attributed the enhanced anti-
microbial effect of the gold nanoparticles loaded on the
lysozyme microbubbles to improved binding and, conse-
quently, increased interaction of the bacteria with the
surface of the lysozyme-microbubbles. Contrarily, gold
nanoparticles alone had an antibacterial rate of »50% at
3 h in the Mahalingam et al. (2015) study. The difference
in antibacterial activity of gold nanoparticles could be
explained by the different bacteria employed. Combin-
ing these lysozyme-coated microbubbles with ultrasound
could have further enhanced the antimicrobial properties
as Liao et al. (2017) observed when using them in their
in vitro and in vivo study. Sonobactericide used against
P. acnes had an enhanced antibacterial effect and
resulted in a 1.45-fold reduction in inflammatory reac-
tions relative to lysozyme-coated microbubbles alone.
Furthermore, after 13 d of treatment, inflammation was
no longer observed.
Vancomycin-loaded nanodroplets (Argenziano et al.
2017), in the absence of ultrasound, were significantly
more effective at an earlier time point than vancomycin
alone or non-loaded nanodroplets alone in killing plank-
tonic MRSA (isolated from human ulcerated wounds).
The authors attributed their findings to the time-sustained
release of vancomycin from the loaded nanodroplets.
However, the altered charge could also have played a role
as vancomycin is positively charged and the vancomycin-
loaded nanodroplets are negatively charged. Ultrasound
exposure significantly enhanced vancomycin delivery
from the loaded nanodroplets ex vivo through non-
infected porcine skin, indicating the potential to treat skin
infections (Argenziano et al. 2017).CLINICAL TRANSLATION OF
SONOBACTERICIDE
Diagnostic ultrasound contrast examinations are
performed worldwide (Madsen and Rasmussen 2011;
Wei 2012; Alzaraa et al. 2013; Nolsoe and Lorentzen
2016), including for the detection of the metastatic
spread of bacterial infective endocarditis (Menozzi et al.
2013a, 2013b). Fifteen of the 27 sonobactericide studies
(56%) used microbubbles that are clinically approved,
by the FDA and European Medicines Agency, which
could help with the translation of sonobactericide into
the clinic. Contrarily, sonobactericide with custom-made
microbubbles containing Triton (Halford et al. 2012) is
not translatable because this surfactant is toxic to cells
(Jahan et al. 2008; Koley and Bard 2010). The ideal
characteristics of a clinically relevant treatment can be
broadly described as improved patient outcomes, reduc-
tion in treatment times and practical implementation in
the clinic. More specifically, broad-spectrum bactericidal
activity, low risk for inducing resistance and minimal
mammalian cell cytotoxicity could be considered. The
reader is referred to two review articles that provide con-
ceptional discussions on the ideal antibiotic that could
aid sonobactericide strategies (Lewis 2013, Gajdacs
2019). The use of clinically relevant animal models of
biofilm would help translate the development of sono-
bactericide. For example, Lin et al. (2015) used a peri-
prosthetic infection rabbit tibia model. However,
periprosthetic joint infection models have limited trans-
lational value as described in the review by Carli et al.
(2016). While proposing criteria for an optimal animal
model, this review stresses the critical importance of ani-
mal, pathogen, implant and outcome measurement selec-
tion and a method that replicates the “human”
periprosthetic environment, wherein at least one of these
areas current models fall short.
The choice of ultrasound insonification parameters
is important for the clinical translation of sonobacteri-
cide. A wide frequency range (tens of kilohertz to 1.3
MHz) has been reported for sonobactericide (see
Table 1), along with pulsed (Vollmer et al. 1998; Lin
et al. 2015; Horsley et al. 2019), continuous wave (Zhu
et al. 2013; Fu et al. 2019) or intermittent (Agarwal et al.
2014; Lattwein et al. 2018) ultrasound in sonification.
More studies directly investigating different ultrasound
parameters should be performed to better understand the
effect they have on sonobactericide. The choice of fre-
quency and exposure parameters needs to focus on
safety, efficacy and compatibility with existing clinical
workflows for rapid clinical translation. Several in vitro
studies have been conducted in sonication baths at fre-
quencies ranging from 2080 kHz (Zhu et al. 2013,
2014), which are likely not directly suitable for in vivo
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et al. 2015; Hu et al., 2018b) and gene transfer equip-
ment (Dong et al. 2013, 2017; Fu et al. 2019) have also
been adapted for sonobactericide studies. Development
of specialized probes may be necessary for treating bio-
films that are not easily accessible or where a small geo-
metric footprint may be needed. Ultrasonic energy may
be delivered to infected areas either extracorporeally or
using catheter-based ultrasound probes. Catheters have
been reported previously for sonothrombolysis (Owens
2008; Kim et al. 2017), and could be investigated for
sonobactericide in vascular organs.
Microbubble concentration, type and route depend
on the location of the biofilm being treated. Microbub-
bles can be delivered intravenously, intra-arterially or by
direct injection into the site of interest (Goldberg et al.
1994). When necessary, high concentrations can be
achieved site-specifically by local infusion of microbub-
bles. On the other hand, delivering microbubbles to bio-
film infections associated with prosthetic joints may be
challenging because the biofilm is typically located
within the joint space (McConoughey et al. 2014). In the
case of bacterial infective endocarditis, contact between
the microbubbles and the biofilm may be hampered by
rapid pulsatile blood flow. Targeting the microbubbles to
the biofilm could further aid in therapeutic efficacy.
Clinical phase 0 trials have successfully been completed
for ultrasound molecular imaging of prostate, ovarian
and breast cancer using targeted microbubbles (Smeenge
et al. 2017; Willmann et al. 2017), thereby paving the
















Fig. 6. Different time scales of the theraaureus biofilm-targeted microbubbles developed by
Anastasiadis et al. (2014) lack clinical translation
because the P. aeruginosa lectin used as ligand causes
red blood cell agglutination (Gilboa-Garber and Sudake-
vitz 1999), and the protein A antibody used as ligand
must compete with host antibodies that cover protein A
(Br€oker et al. 2014). For other potential targeting possi-
bilities, the reader is referred to the reviews by van Oos-
ten et al. (2015) and Koo et al. (2017).CONCLUSIONS AND FUTURE PERSPECTIVES
Therapeutic effects of sonobactericide can include
direct bacterial killing, biofilm degradation and dispersal
and increased or synergistic therapeutic effectiveness of
antimicrobials or other drugs, all resulting from the phys-
ical phenomena of ultrasound combined with cavitation
nuclei aided by the addition of an antimicrobial agent. It
is the different time scales at which these actions occur
that makes sonobactericide challenging, as illustrated in
Figure 6. The time scale of the microbubble vibration is
on the order of microseconds in a megahertz ultrasound
field, which is many orders of magnitude smaller than
the time scale of physiologic effects (milliseconds), let
alone that of biological effects (seconds to minutes) and
clinical relevance (days to months). The link between,
and the mechanistic aspects of, cavitation nucleation, the
effect on (intracellular) bacteria/biofilms and antimicro-
bial drug release and uptake need to be elucidated in
future studies to efficiently treat bacterial infections.dispersal
ericide
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efficacy has received limited attention. For example, the
age and composition of the biofilm (Shen et al. 2010)
may contribute to its resilience to sonobactericide. The
antibiotic penetration through biofilm decreases appreci-
ably with the age of the biofilm (Carmen et al. 2004).
Additionally, biofilms formed in vivo may differ in com-
position and morphology from in vitro biofilm models
(Bjarnsholt et al. 2013). For example, recent research
has indicated that infective endocarditis can be a polymi-
crobial infection (Oberbach et al. 2017). These effects
should be elucidated in future pre-clinical and clinical
studies, as also addressed in other reviews (Coenye and
Nelis 2010, Malone et al. 2017).
Nanoscale cavitation nucleating agents such as
nanodroplets and polymeric nanocups (Kwan et al.
2015) could be interesting for sonobactericide as they
could penetrate the biofilm and help nucleate cavitation
throughout the biofilm. In particular, the process of drop-
let vaporization may exert mechanical forces on the bio-
film in addition to antibiotic activity (Guo et al. 2017).
Nanodroplets can nucleate sustained cavitation in closed
fluid spaces (Chen et al. 2013). Polymeric nanocups
nucleate inertial cavitation activity with thresholds
inversely proportional to size. For example, nanocups
with mean sizes of 180 and 600 nm have been reported
to nucleate inertial cavitation at peak rarefactional pres-
sures of 3 and 0.5 MPa, respectively (Kwan et al. 2015).
These agents have not yet been investigated for treating
biofilms. Despite the potential advantages offered by
nanodroplets and nanocups, these agents are not yet clin-
ically approved or readily available. Therefore, sonobac-
tericide using these agents may not be clinically feasible
in the near future.
Recalcitrant biofilms may be treated with shock
waves (Gnanadhas et al. 2015; Qi et al. 2016) or histo-
tripsy (Xu et al. 2012; Bigelow et al. 2017). Jetting from
shock waves has been used in the clinic to destroy kid-
ney stones and gallstones with lithotripsy (Vakil and
Everbach 1993). Highly focused image-guided ultra-
sound beams can help concentrate acoustic energy at the
biofilm site, while avoiding collateral damage. Histo-
tripsy can be combined with a cavitation nucleation
agent, such as phase-shift nanodroplets (Vlaisavljevich
et al. 2013) and echogenic liposomes (Bader et al.
2016b), to lower the acoustic pressure thresholds for
ablation, which could potentially improve the safety pro-
file of treatment. Another potential application to treat
biofilm infections harnessing sound is an ultrasonically
activated stream. Birkin et al. (2015) reported that by
applying low-amplitude ultrasound (135 kHz, 120250
kPa) through a liquid stream directed at a surface, endog-
enous cavitation nuclei can be sufficiently activated at
the solid/liquid interface to disrupt biofilm.Combining ultrasound, cavitation nuclei and antibi-
otic therapy with matrix-degrading enzymes implicated in
biofilm dispersal, such as glycosidases, proteases and
deoxyribonucleases (Kaplan 2010; Zhu et al. 2013; Li
et al. 2015), is a promising strategy for treating biofilms.
Our group has recently reported the use of rtPA, a clini-
cally approved fibrinolytic agent, along with Definity
microbubbles, an antibiotic and 120-kHz intermittent
ultrasound for sonobactericide in an in vitro flow model
(Lattwein et al. 2018). This strategy could be promising
for treating biofilms that have fibrin as a primary struc-
tural component. The microstreaming produced by cavita-
tion nuclei (Kooiman et al. 2014) can help remove biofilm
degradation products and enhance the delivery of drugs,
similar to sonothrombolysis studies (Bader et al. 2016a).
Although the feasibility of biofilm dispersal has been
reported in previous studies (Kaplan 2010), more work
needs to be done to elucidate the efficacy of combination
therapy with matrix-degrading enzymes, ultrasound and
microbubbles. Future research could also include the
interference of quorum sensing, which is bacterial com-
munication that regulates several virulence pathways
through signaling molecules and increases with cell den-
sity (Whiteley et al. 2017). Because of the high potential
of this approach, many compounds are under develop-
ment that could be combined with sonobactericide to
enhance efficacy (Fleitas Martınez et al. 2019). In addi-
tion, it is unknown if sonobactericide has an effect on quo-
rum sensing without these agents.
The safety and efficacy of sonobactericide are para-
mount. Accurate characterization of the acoustic fields
(ter Haar et al. 2011) and parameters used, standardiza-
tion of protocols for the assessment of treatment efficacy
and development of in vitro and pre-clinical models that
mimic the in vivo milieu will help accelerate the transi-
tion of sonobactericide to the clinic. In addition, enabling
image guidance methods, such as active (Miller et al.
2016) or passive cavitation imaging (Haworth et al.
2017) and real-time feedback (Sun et al. 2017), may help
monitor treatment progress, standardize the acoustic
dose and aid in improving the safety and efficacy of
in situ destruction of biofilms.
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